The following is a summary of “REmoval of cytokines during CArdiac surgery (RECCAS): a randomised controlled trial,” published in the December 2024 issue of Critical Care by Hohn et al.
Chimeric antigen receptor T-cell or CAR T therapy shows promise for patients with refractory or relapsing B-cell lymphomas.
The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak ...
T-cell therapy is a type of cancer immunotherapy where patients' T-cells are collected and genetically modified to produce ...
Bicistronic CAR T-cell therapy can produce durable complete responses in pediatric patients with relapsed or refractory B-ALL, data suggest.
A recent review published in eGastroenterology discusses recent advancements in understanding alcohol-associated liver ...
The advent of cellular therapies, such as chimeric antigen receptor T-cell therapy, has revolutionized the field of ...
PRINCETON, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO) announces the commencement of its Rights Offering, previously detailed in our December 9, 2024 announcement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback